Core Viewpoint - The company anticipates that its domestic medical aesthetics segment will have several products approved for market launch by 2026, indicating a strategic focus on expanding its offerings in this growing industry [1] Product Launch Expectations - The company plans to launch the following products in the domestic medical aesthetics market by 2026: - YY001, a recombinant type A botulinum toxin for injection - Ellansé® M-type, aimed at improving temporal hollowing - A multifunctional platform machine combining V30 radiofrequency, intense pulsed light, and Nd:YAG laser technology - MaiLi® Precise, a new hyaluronic acid filler containing lidocaine for the treatment of infraorbital hollows [1]